Most smokers who try to quit do so without assistance. However, only 3–6% of quit attempts without assistance are successful long-term. Behavioral counseling and medications each increase the rate of successfully quitting smoking, and a combination of behavioral counseling with a medication such as bupropion is more effective than either intervention alone. A meta-analysis from 2018, conducted on 61 randomized controlled trials, showed that among people who quit smoking with a cessation medication (and some behavioral help), approximately 20% were still nonsmokers a year later, as compared to 12% who did not take medication.
In nicotine-dependent smokers, quitting smoking can lead to symptoms of nicotine withdrawal such as nicotine cravings, anxiety, irritability, depression, and weight gain.: 2298 Professional smoking cessation support methods generally attempt to address nicotine withdrawal symptoms to help the person break free of nicotine addiction.
Smoking cessation methods
It is common for ex-smokers to have made a number of attempts (often using different approaches on each occasion) to stop smoking before achieving long-term abstinence. Over 74.7% of smokers attempt to quit without any assistance, otherwise known as "cold turkey", or with home remedies. Previous smokers make between an estimated 6 and 30 attempts before successfully quitting. Identifying which approach or technique is eventually most successful is difficult; it has been estimated, for example, that only about 4% to 7% of people are able to quit smoking on any given attempt without medicines or other help. The majority of quit attempts are still unassisted, though the trend seems to be shifting. In the U.S., for example, the rate of unassisted quitting fell from 91.8% in 1986 to 52.1% during 2006 to 2009. The most frequent unassisted methods were "cold turkey", a term that has been used to mean either unassisted quitting or abrupt quitting and "gradually decreased number" of cigarettes, or "cigarette reduction".
"Cold turkey" is a colloquial term indicating abrupt withdrawal from an addictive drug, and in this context indicates sudden and complete cessation of all nicotine use. In three studies, it was the quitting method cited by 76%, 85%, or 88% of long-term successful quitters. In a large British study of ex-smokers in the 1980s, before the advent of pharmacotherapy, 53% of the ex-smokers said that it was "not at all difficult" to stop, 27% said it was "fairly difficult", and the remaining 20% found it very difficult. Studies have found that two-thirds of recent quitters reported using the cold turkey method and found it helpful.
Cutting down to quit
Gradual reduction involves slowly reducing one's daily intake of nicotine. This can theoretically be accomplished through repeated changes to cigarettes with lower levels of nicotine, by gradually reducing the number of cigarettes smoked each day, or by smoking only a fraction of a cigarette on each occasion. A 2009 systematic review by researchers at the University of Birmingham found that gradual nicotine replacement therapy could be effective in smoking cessation. There is no significant difference in quit rates between smokers who quit by gradual reduction or abrupt cessation as measured by abstinence from smoking of at least six months from the quit day. The same review also looked at five pharmacological aids to reduction. When reducing the number of smoked cigarettes, it found some evidence that additional varenicline or fast-acting nicotine replacement therapy can have positive effects on quitting for six months and longer.
The American Cancer Society notes that "Studies in medical journals have reported that about 25% of smokers who use medicines can stay smoke-free for over 6 months." Single medications include:
Nicotine replacement therapy (NRT): Five medications have been approved by the U.S. Food and Drug Administration (FDA) deliver nicotine in a form that does not involve the risks of smoking: transdermal nicotine patches, nicotine gum, nicotine lozenges, nicotine inhalers, nicotine oral sprays, and nicotine nasal sprays. High-quality evidence indicates that these forms of NRT improve the success rate for people who attempt to stop smoking. NRTs are meant to be used for a short period of time and should be tapered down to a low dose before stopping. NRTs increase the chance of stopping smoking by 50 to 60% compared to placebo or to no treatment. Some reported side effects are local slight irritation (inhalers and sprays) and non-ischemic chest pain (rare). Others include mouth soreness and dyspepsia (gum), nausea or heartburn (lozenges), as well as sleep disturbances, insomnia, and a local skin reaction (patches).
A study found that 93% of over-the-counter NRT users relapse and return to smoking within six months.
There is weak evidence that adding mecamylamine to nicotine is more effective than nicotine alone.
Antidepressants: The antidepressant bupropion is considered a first-line medication for smoking cessation and has been shown in many studies to increase long-term success rates. Although bupropion increases the risk of getting adverse events, there is no clear evidence that the drug has more or less adverse effects when compared to placebo. Nortriptyline produces significant rates of abstinence versus placebo.
Varenicline decreases the urge to smoke and reduces withdrawal symptoms and is therefore considered a first-line medication for smoking cessation. The number of people stopping smoking with varenicline is higher than with bupropion or NRT. Varenicline more than doubled the chances of quitting compared to placebo, and was also as effective as combining two types of NRT. 2 mg/day of varenicline has been found to lead to the highest abstinence rate (33.2%) of any single therapy, while 1 mg/day leads to an abstinence rate of 25.4%. A 2016 systematic review and meta-analysis of randomized controlled trials concluded there is no evidence supporting a connection between varenicline and increased cardiovascular events. Concerns arose that varenicline may cause neuropsychiatric side effects, including suicidal thoughts and behavior. However, more recent studies indicate less serious neuropsychiatric side effects. For example, a 2016 study involving 8,144 patients treated at 140 centers in 16 countries "did not show a significant increase in neuropsychiatric adverse events attributable to varenicline or bupropion relative to nicotine patch or placebo". No link between depressed moods, agitation or suicidal thinking in smokers taking varenicline to decrease the urge to smoke has been identified. For people who have pre-existing mental health difficulties, varenicline may slightly increase the risk of experiencing these neuropsychiatric adverse events.
Clonidine may reduce withdrawal symptoms and "approximately doubles abstinence rates when compared to a placebo", but its side effects include dry mouth and sedation, and abruptly stopping the drug can cause high blood pressure and other side effects.
Previously, rimonabant which is a cannabinoid receptor type 1 antagonist was used to help in quitting and to moderate the expected weight gain. But it is important to know that the manufacturers of rimonabant and taranabant stopped production in 2008 due to serious CNS side effects.
The 2008 US Guideline specifies that three combinations of medications are effective:: 118–120
Long-term nicotine patch and ad libitum NRT gum or spray
Nicotine patch and nicotine inhaler
Nicotine patch and bupropion (the only combination that the US FDA has approved for smoking cessation)
A meta-analysis from 2018, conducted on 61 RCTs, showed that during their first year of trying to quit, approximately 80% of the participants in the studies who got drug assistance (bupropion, NRT, or varenicline) returned to smoking while 20% continued to not smoke for the entire year (i.e.: remained sustained abstinent). In comparison, 12% the people who got placebo kept from smoking for (at least) an entire year. This makes the net benefit of the drug treatment to be 8% after the first 12 months. In other words, out of 100 people who will take medication, approximately 8 of them would remain non-smoking after one year thanks to the treatment. During the course of one year, the benefit from using smoking cessation medications (Bupropion, NRT, or varenicline) decreases from 17% in 3 months, to 12% in 6 months to 8% in 12 months.
Community interventions using "multiple channels to provide reinforcement, support and norms for not smoking" may have an effect on smoking cessation outcomes among adults. Specific methods used in the community to encourage smoking cessation among adults include:
Policies making workplaces and public places smoke-free. It is estimated that "comprehensive clean indoor laws" can increase smoking cessation rates by 12%–38%. In 2008, the New York State of Alcoholism and Substance Abuse Services banned smoking by patients, staff, and volunteers at 1,300 addiction treatment centers.
Voluntary rules making homes smoke-free, which are thought to promote smoking cessation.
Initiatives to educate the public regarding the health effects of second-hand smoke, including the significant dangers of secondhand smoke infiltration for residents of multi-unit housing.
Increasing the price of tobacco products, for example by taxation. The US Task Force on Community Preventive Services found "strong scientific evidence" that this is effective in increasing tobacco use cessation : 28–30 It is estimated that an increase in price of 10% will increase smoking cessation rates by 3–5%.
Mass media campaigns. There is evidence to suggest that when combined with other types of interventions, mass media campaigns may of benefit.: 30–32 
Weak evidence suggests that imposing institutional level smoking bans in hospitals and prisons may reduce smoking rates and second hand smoke exposure.
Interactive web-based and stand-alone computer programs and online communities which assist participants in quitting. For example, "quit meters" keep track of statistics such as how long a person has remained abstinent. Computerised interventions and interactive tailored interventions may be promising,: 93–94 however the evidence base for such interventions is weak.
A mobile phone-based intervention where automated, supportive text messages are sent alongside other forms of support helps more people quit smoking: "The current evidence supports a beneficial impact of mobile phone-based cessation interventions on six-month cessation outcomes. A 2011 randomized trial of mobile phone-based smoking cessation support in the UK found that a Txt2Stop cessation program significantly improved cessation rates at 6 months. A 2013 meta-analysis also noted "modest benefits" of mobile health interventions.
Interactive web-based programs combined with a Mobile phone: Two RCTs documented long-term treatment effects (abstinence rate: 20-22 %) of such interventions.
The Great American Smokeout is an annual event that invites smokers to quit for one day, hoping they will be able to extend this forever.
Smoking-cessation support is often offered over the telephone quitlines (e.g., the US toll-free number 1-800-QUIT-NOW), or in person. Three meta-analyses have concluded that telephone cessation support is effective when compared with minimal or no counselling or self-help, and that telephone cessation support with medication is more effective than medication alone,: 91–92 : 40–42 and that intensive individual counselling is more effective than the brief individual counselling intervention. A small tendency towards better results for more intensive counselling was also observed in another meta-analysis. This analysis distinguished between reactive (smokers calling quitlines) and proactive (smokers receiving calls) interventions. For people who called the quitline themselves, additional calls helped to quit smoking for six months or longer. When proactively initiating contact with a smoker, telephone-counselling increased chances of smoking cessation by 2–4% compared with people who received no calls. There is about 10% to 25% increase of the chance of smoking cessation success with the more behavioral support provided in person or via telephone when used as an adjunct to pharmacotherapy.
Online social cessation networks attempt to emulate offline group cessation models using purpose built web applications. They are designed to promote online social support and encouragement for smokers when (usually automatically calculated) milestones are reached. Early studies have shown social cessation to be especially effective with smokers aged 19–29.
Group or individual psychological support can help people who want to quit. Recently, group therapy has been found to be more helpful than self-help and some other individual intervention. The psychological support form of counselling can be effective alone; combining it with medication is more effective, and the number of sessions of support with medication correlates with effectiveness.: 89–90, 101–103  The counselling styles that have been effective in smoking cessation activities include motivational interviewing,cognitive behavioral therapy and acceptance and commitment therapy, methods based on cognitive behavioral therapy.
The Freedom From Smoking group clinic includes eight sessions and features a step-by-step plan for quitting smoking. Each session is designed to help smokers gain control over their behavior. The clinic format encourages participants to work on the process and problems of quitting both individually and as part of a group.
Multiple formats of psychosocial interventions increase quit rates: 10.8% for no intervention, 15.1% for one format, 18.5% for 2 formats, and 23.2% for three or four formats.: 91
The transtheoretical model, including "stages of change", has been used in tailoring smoking cessation methods to individuals, however, there is some evidence to suggest that "stage-based self-help interventions (expert systems and/or tailored materials) and individual counselling are neither more nor less effective than their non-stage-based equivalents."
Setting a quit plan and quit date
Most smoking cessation resources such as the Centers for Disease Control and Prevention (CDC) and The Mayo Clinic encourage smokers to create a quit plan, including setting a quit date, which helps them anticipate and plan ahead for smoking challenges. A quit plan can improve a smoker's chance of a successful quit as can setting Monday as the quit date, given that research has shown that Monday more than any other day is when smokers are seeking information online to quit smoking and calling state quit lines.
Some health organizations manage text messaging services to help people avoid smoking
Self-help materials may produce a small increase in quit rates specially when there is no other supporting intervention form. "The effect of self-help was weak", and the number of types of self-help did not produce higher abstinence rates.: 89–91 Nevertheless, self-help modalities for smoking cessation include:
Spirituality: In one survey of adult smokers, 88% reported a history of spiritual practice or belief, and of those more than three-quarters were of the opinion that using spiritual resources may help them quit smoking.
A review of mindfulness training as a treatment for addiction showed reduction in craving and smoking following training.
Physical activities help in the maintenance of smoking cessation even if there is no conclusive evidence of the most appropriate exercise intensity.
Various methods exist which allow a smoker to see the impact of their tobacco use, and the immediate effects of quitting. Using biochemical feedback methods can allow tobacco-users to be identified and assessed, and the use of monitoring throughout an effort to quit can increase motivation to quit. Evidence wise, little is known about the effects of using biomechanical tests to determine a person's risk related to smoking cessation.
Breath carbon monoxide (CO) monitoring: Because carbon monoxide is a significant component of cigarette smoke, a breath carbon monoxide monitor can be used to detect recent cigarette use. Carbon monoxide concentration in breath has been shown to be directly correlated with the CO concentration in blood, known as percent carboxyhemoglobin. The value of demonstrating blood CO concentration to a smoker through a non-invasive breath sample is that it links the smoking habit with the physiological harm associated with smoking. Within hours of quitting, CO concentrations show a noticeable decrease, and this can be encouraging for someone working to quit. Breath CO monitoring has been utilized in smoking cessation as a tool to provide patients with biomarker feedback, similar to the way in which other diagnostic tools such as the stethoscope, the blood pressure cuff, and the cholesterol test have been used by treatment professionals in medicine.
Cotinine: Cotinine, a metabolite of nicotine, is present in smokers. Like carbon monoxide, a cotinine test can serve as a reliable biomarker to determine smoking status. Cotinine levels can be tested through urine, saliva, blood, or hair samples, with one of the main concerns of cotinine testing being the invasiveness of typical sampling methods.
While both measures offer high sensitivity and specificity, they differ in usage method and cost. As an example, breath CO monitoring is non-invasive, while cotinine testing relies on a bodily fluid. These two methods can be used either alone or together, for example, in a situation where abstinence verification needs additional confirmation.
Competitions and incentives
Financial or material incentives to entice people to quit smoking improves smoking cessation while the incentive is in place. Competitions that require participants to deposit their own money, "betting" that they will succeed in their efforts to quit smoking, appear to be an effective incentive. However, in head-to-head comparisons with other incentive models such as giving participants NRT or placing them in a more typical rewards program, it is more difficult to recruit participants for this type of contest. There is evidence that incentive programs may be effective for pregnant mothers who smoke. As of 2019, there is an insufficient number of studies on "quit and win" and other competition-based interventions and results from the existing studies were inconclusive.
A 2008 Cochrane review of smoking cessation activities in work-places concluded that "interventions directed towards individual smokers increase the likelihood of quitting smoking". A 2010 systematic review determined that worksite incentives and competitions needed to be combined with additional interventions to produce significant increases in smoking cessation rates.
Interventions delivered via healthcare providers and healthcare systems have been shown to improve smoking cessation among people who visit those services.
A clinic screening system (e.g., computer prompts) to identify whether or not a person smokes doubled abstinence rates, from 3.1% to 6.4%.: 78–79 Similarly, the Task Force on Community Preventive Services determined that provider reminders alone or with provider education are effective in promoting smoking cessation.: 33–38
A 2008 Guideline meta-analysis estimated that physician advice to quit smoking led to a quit rate of 10.2%, as opposed to a quit rate of 7.9% among patients who did not receive physician advice to quit smoking.: 82–83 Even brief advice from physicians may have "a small effect on cessation rates" and there is evidence that the physicians' probability of giving smoking cessation advice declines with the person who smokes age. There is evidence that only 81% of smokers age 50 or greater received advice on quitting from their physicians in the preceding year.
For one-to-one or person-to-person counselling sessions, the duration of each session, the total amount of contact time, and the number of sessions all correlated with the effectiveness of smoking cessation. For example, "Higher intensity" interventions (>10 minutes) produced a quit rate of 22.1% as opposed to 10.9% for "no contact" over 300 minutes of contact time produced a quit rate of 25.5% as opposed to 11.0% for "no minutes" and more than 8 sessions produced a quit rate of 24.7% as opposed to 12.4% for 0–1 sessions.: 83–86
Both physicians and non-physicians increased abstinence rates compared with self-help or no clinicians.: 87–88 For example, a Cochrane review of 58 studies found that nursing interventions increased the likelihood of quitting. Another review found some positive effects when trained community pharmacists support the customers in their smoking cessation trials.
Dental professionals also provide a key component in increasing tobacco abstinence rates in the community through counseling patients on the effects of tobacco on oral health in conjunction with an oral exam.
According to the 2008 Guideline, based on two studies the training of clinicians in smoking cessation methods may increase abstinence rates;: 130 however, a Cochrane review found and measured that such training decreased smoking in patients.
Reducing or eliminating the costs of cessation therapies for smokers increased quit rates in three meta-analyses.: 139–140 : 38–40 
In one systematic review and meta-analysis, multi-component interventions increased quit rates in primary care settings. "Multi-component" interventions were defined as those that combined two or more of the following strategies known as the "5 A's":: 38–43
Ask — Systematically identify all tobacco users at every visit
Advise — Strongly urge all tobacco users to quit
Breath CO monitor displaying carbon monoxide concentration of an exhaled breath sample (in ppm) with its corresponding percent concentration of carboxyhemoglobin
Assess — Determine willingness to make a quit attempt
Assist — Aid the patient in quitting (provide counselling-style support and medication)
Nicotine replacement therapy (NRT) is the general term for using products that contain nicotine but not tobacco to aid cessation of smoking. These include nicotine lozenges that are sucked, nicotine gum and inhalers, nicotine patches, as well as electronic cigarettes. In a review of 136 NRT-related Cochrane Tobacco Addiction Group studies, strong evidence supported NRT use in increasing the chances of successfully quitting smoking by 50 to 60% in comparison to placebo or a non-NRT control group.
Electronic cigarette: There is high‐certainty evidence that ECs with nicotine increase quit rates compared to NRT and moderate‐certainty evidence that they increase quit rates compared to ECs without nicotine. Little is known regarding the long-term harms related to vaping. A 2016 UK Royal College of Physicians report supports the use of e-cigarettes as a smoking cessation tool. A 2015 Public Health England report stated that "Smokers who have tried other methods of quitting without success could be encouraged to try e-cigarettes (EC) to stop smoking and stop smoking services should support smokers using EC to quit by offering them behavioural support."
Acupuncture: Acupuncture has been explored as an adjunct treatment method for smoking cessation. A 2014 Cochrane review was unable to make conclusions regarding acupuncture as the evidence is poor. A 2008 guideline found no difference between acupuncture and placebo, found no scientific studies supporting laser therapy based on acupuncture principles but without the needles.: 99
Chewing cinnamon sticks or gum has been recommended when trying to quit the use of tobacco.
Hypnosis: Hypnosis often involves the hypnotherapist suggesting to the patient the unpleasant outcomes of smoking. Clinical trials studying hypnosis and hypnotherapy as a method for smoking cessation have been inconclusive.: 100  A Cochrane review was unable to find evidence of benefit of hypnosis in smoking cessation, and suggested if there is a beneficial effect, it is small at best. However, a randomized trial published in 2008 found that hypnosis and nicotine patches "compares favorably" with standard behavioral counseling and nicotine patches in 12-month quit rates.
Herbal medicine: Many herbs have been studied as a method for smoking cessation, including lobelia and St John's wort. The results are inconclusive, but St. Johns Wort shows few adverse events. Lobelia has been used to treat respiratory diseases like asthma and bronchitis, and has been used for smoking cessation because of chemical similarities to tobacco; lobelia is now listed in the FDA's Poisonous Plant Database. Lobelia can still be found in many products sold for smoking cessation and should be used with caution.
Smokeless tobacco: There is little smoking in Sweden, which is reflected in the very low cancer rates for Swedish men. Use of snus (a form of steam-pasteurized, rather than heat-pasteurized, air-cured smokeless tobacco) is an observed cessation method for Swedish men and even recommended by some Swedish doctors. However, the report by the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) concludes "STP (smokeless tobacco products) are addictive and their use is hazardous to health. Evidence on the effectiveness of STP as a smoking cessation aid is insufficient." A recent national study on the use of alternative tobacco products, including snus, did not show that these products promote cessation.
Aversion therapy: It is a method of treatment works by pairing the pleasurable stimulus of smoking with other unpleasant stimuli. A Cochrane review reported that there is insufficient evidence of its efficacy.
Nicotine vaccines: Nicotine vaccines (e.g., NicVAX and TA-NIC) work by reducing the amount of nicotine reaching the brain; however, this method of therapy needs more investigations to establish its role and determine its side effects.
Technology and machine learning: Research studies using machine learning or artificial intelligence tools to provide feedback and communication with those who are trying to quit smoking are increasing, yet the findings are so far inconclusive.
Psilocybin has been being investigated as a potential smoking cessation aid for several years. In 2021, Johns Hopkins Medicine has been awarded a grant from the National Institutes of Health to explore the potential impacts of psilocybin and talk therapy on tobacco addiction.
Smoking cessation methods for special populations
Children and adolescents
Methods used with children and adolescents include:
Cochrane reviews, mainly of studies combining motivational enhancement and psychological support, concluded that "complex approaches" for smoking cessation among young people show promise. The 2008 US Guideline recommends counselling-style support for adolescent smokers on the basis of a meta-analysis of seven studies.: 159–161 Neither the Cochrane review nor the 2008 Guideline recommends medications for adolescents who smoke.
Smoking during pregnancy can cause adverse health effects in both the woman and the fetus. The 2008 US Guideline determined that "person-to-person psychosocial interventions" (typically including "intensive counseling") increased abstinence rates in pregnant women who smoke to 13.3%, compared with 7.6% in usual care.: 165–167 Mothers who smoke during pregnancy have a greater tendency towards premature births. Their babies are often underdeveloped, have smaller organs, and weigh much less than the normal baby. In addition, these babies have weaker immune systems, making them more susceptible to many diseases such as middle ear inflammations and asthmatic bronchitis as well as metabolic conditions such as diabetes and hypertension, all of which can bring significant morbidity. Additionally, a study published by American Academy of Pediatrics shows that smoking during pregnancy increases the chance of sudden unexpected infant death (SUID). There is also an increased chance that the child will be a smoker in adulthood. A systematic review showed that psychosocial interventions help women to stop smoking in late pregnancy and can reduce the incidence of low birthweight infants.
It is a myth that a female smoker can cause harm to a fetus by quitting immediately upon discovering she is pregnant. This idea is not based on any medical study or fact.
In a UK study that included 1140 pregnant women, e-cigarettes were found to be as effective as nicotine patches at helping pregnant women to quit smoking. The safety of the two products was also similar.
Studies across 20 countries show a strong association between patients with schizophrenia and smoking. People with schizophrenia are much more likely to smoke than those without the disease. For example, in the United States, 80% or more of people with schizophrenia smoke, compared to 20% of the general population in 2006.
Percent increase of success for six months over unaided attempts for each type of quitting (chart from West & Shiffman based on Cochrane review data: 59
Smokers who are hospitalised may be particularly motivated to quit.: 149–150 A 2012 Cochrane review found that interventions beginning during a hospital stay and continuing for one month or more after discharge were effective in producing abstinence.
Patients undergoing elective surgery may get benefits of preoperative smoking cessation interventions, when starting 4–8 weeks before surgery with weekly counseling intervention for behavioral support and use of nicotine replacement therapy. It is found to reduce the complications and the number of postoperative morbidity.
People who have mood disorders or attention deficit hyperactivity disorders have a greater chance to begin smoking and lower chance to quit smoking. A higher correlation with smoking has also been seen in people diagnosed with major depressive disorder at any time throughout the duration of their lifetime as compared to those without the diagnosis. Success rates in quitting smoking were lower for those with a major depressive disorder diagnosis versus people without the diagnosis. Exposure of cigarette smoke early on in life during pregnancy, infancy, or adolescence may negatively impact a child's neurodevelopment and increase the risk of developing anxiety disorders in the future.
Homeless and poverty
Homelessness doubles the likelihood of an individual currently being a smoker. This is independent of other socioeconomic factors and behavioral health conditions. Homeless individuals have the same rates of the desire to quit smoking but are less likely than the general population to be successful in their attempt to quit.
In the United States, 60–80% of homeless adults are current smokers. This is a considerably higher rate than that of the general adult population of 19%. Many current smokers who are homeless report smoking as a means of coping with "all the pressure of being homeless." The perception that homeless people smoking is "socially acceptable" can also reinforce these trends.
Americans under the poverty line have higher rates of smoking and lower rates of quitting than those over the poverty line. While the homeless population as a whole is concerned about short-term effects of smoking, such as shortness of breath of recurrent bronchitis, they are not as concerned with long-term consequences. The homeless population has unique barriers to quit smoking such as unstructured days, the stress of finding a job, and immediate survival needs that supersede the desire to quit smoking.
These unique barriers can be combated through pharmacotherapy and behavioral counseling for high levels of nicotine dependence, emphasis of immediate financial benefits to those who concern themselves with the short-term over the long-term, partnering with shelters to reduce the social acceptability of smoking in this population, and increased taxes on cigarettes and on alternative tobacco products to further make the addiction more difficult to fund.
People in treatment for or recovery from substance use disorders
Over three-quarters of people in treatment for substance use are current smokers. Providing counseling and pharmacotherapy (nicotine replacement therapy such as patches or gum, varenicline, and/or bupropion) increases tobacco abstinence without increasing the risk of returning to other substance use.
Comparison of success rates
Comparison of success rates across interventions can be difficult because of different definitions of "success" across studies. Robert West and Saul Shiffman, authorities in this field recognized by government health departments in a number of countries,: 73, 76, 80 have concluded that, used together, "behavioral support" and "medication" can quadruple the chances that a quit attempt will be successful.
A 2008 systematic review in the European Journal of Cancer Prevention found that group behavioural therapy was the most effective intervention strategy for smoking cessation, followed by bupropion, intensive physician advice, nicotine replacement therapy, individual counselling, telephone counselling, nursing interventions, and tailored self-help interventions; the study did not discuss varenicline.
Factors affecting success
Individuals who sustained damage to the insula were able to more easily abstain from smoking.
Quitting can be harder for individuals with dark pigmented skin compared to individuals with pale skin since nicotine has an affinity for melanin-containing tissues. Studies suggest this can cause the phenomenon of increased nicotine dependence and lower smoking cessation rate in darker pigmented individuals.
There is an important social component to smoking. The spread of smoking cessation from person to person contributes to the decrease in smoking these years. A 2008 study of a densely interconnected network of over 12,000 individuals found that smoking cessation by any given individual reduced the chances of others around them lighting up by the following amounts: a spouse by 67%, a sibling by 25%, a friend by 36%, and a coworker by 34%. Nevertheless, a Cochrane review determined that interventions to increase social support for a smoker's cessation attempt did not increase long-term quit rates.
Smokers who are trying to quit are faced with social influences that may persuade them to conform and continue smoking. Cravings are easier to detain when one's environment does not provoke the habit. If a person who stopped smoking has close relationships with active smokers, he or she is often put into situations that make the urge to conform more tempting. However, in a small group with at least one other not smoking, the likelihood of conformity decreases.
The social influence to smoke cigarettes has been proven to rely on simple variables. One researched variable depends on whether the influence is from a friend or non-friend. The research shows that individuals are 77% more likely to conform to non-friends, while close friendships decrease conformity. Therefore, if an acquaintance offers a cigarette as a polite gesture, the person who has stopped smoking will be more likely to break his commitment than if a friend had offered. Recent research from the International Tobacco Control (ITC) Four Country Survey of over 6,000 smokers found that smokers with fewer smoking friends were more likely to intend to quit and to succeed in their quit attempt.
Expectations and attitude are significant factors. A self-perpetuating cycle occurs when a person feels bad for smoking yet smokes to alleviate feeling bad. Breaking that cycle can be a key in changing the sabotaging attitude.
The CDC recognizes seven common nicotine withdrawal symptoms that people often face when stopping smoking: "cravings to smoke, feeling irritated, grouchy, or upset, feeling jumpy and restless, having a hard time concentrating, having trouble sleeping, feeling hungry or gaining weight, or feeling anxious, sad or depressed." Studies have shown that use of pharmacotherapies, such as varenicline can be useful in reducing withdrawal symptoms during the quitting process.
Giving up smoking is associated with an average weight gain of 4–5 kilograms (8.8–11.0 lb) after 12 months, most of which occurs within the first three months of quitting.
The possible causes of the weight gain include:
Smoking over-expresses the gene AZGP1 which stimulates lipolysis, so smoking cessation may decrease lipolysis.
Heavy smokers are reported to burn 200 calories per day more than non-smokers eating the same diet. Possible reasons for this phenomenon include nicotine's ability to increase energy metabolism or nicotine's effect on peripheral neurons.
The U.S. Department of Health and Human Services guideline suggests that sustained-release bupropion, nicotine gum, and nicotine lozenge be used "to delay weight gain after quitting." There is not currently enough evidence to suggest one method of weight loss works better than others in preventing weight gain during the smoking cessation process. Regardless of post-cessation weight gain, there is a significant decrease in risk of cardiovascular disease in those who have quit smoking.
Like other physically addictive drugs, nicotine addiction causes a down-regulation of the production of dopamine and other stimulatory neurotransmitters as the brain attempts to compensate for the artificial stimulation caused by smoking. Some studies from the 1990s found that when people stop smoking, depressive symptoms such as suicidal tendencies or actual depression may result, although a recent international study comparing smokers who had stopped for 3 months with continuing smokers found that stopping smoking did not appear to increase anxiety or depression. A 2021 review found that quitting smoking lessens anxiety and depression.
Within 5–10 years, the risk of stroke falls to the same as a non-smoker, and the risks of many cancers (mouth, throat, esophagus, bladder, cervix) decrease significantly
Within 10 years, the risk of dying from lung cancer is cut in half, and the risks of larynx and pancreas cancers decrease
Within 15 years, the risk of coronary heart disease drops to the level of a non-smoker; lowered risk for developing COPD (chronic obstructive pulmonary disease)
The British Doctors Study showed that those who stopped smoking before they reached 30 years of age lived almost as long as those who never smoked. Stopping in one's sixties can still add three years of healthy life. A randomized trial from the U.S. and Canada showed that a smoking cessation program lasting 10 weeks decreased mortality from all causes over 14 years later. A recent article on mortality in a cohort of 8,645 smokers who were followed-up after 43 years determined that "current smoking and lifetime persistent smoking were associated with an increased risk of all-cause, CVD [cardiovascular disease], COPD [chronic obstructive pulmonary disease], and any cancer, and lung cancer mortality."
Another published study, "Smoking Cessation Reduces Postoperative Complications: A Systematic Review and Meta-analysis", examined six randomized trials and 15 observational studies to look at the effects of preoperative smoking cessation on postoperative complications. The findings were: 1) taken together, the studies demonstrated decreased the likelihood of postoperative complications in patients who ceased smoking prior to surgery; 2) overall, each week of cessation prior to surgery increased the magnitude of the effect by 19%. A significant positive effect was noted in trials where smoking cessation occurred at least four weeks prior to surgery; 3) For the six randomized trials, they demonstrated on average a relative risk reduction of 41% for postoperative complications.
Smokers as a percentage of the population for the United States, the Netherlands, Norway, Japan, and Finland
In a 1997 U.S. analysis, the estimated cost per QALY varied by the type of cessation approach, ranging from group intensive counselling without nicotine replacement at $1108 per QALY to minimal counselling with nicotine gum at $4542 per QALY.
Among National Health Service smoking cessation clients in Glasgow, pharmacy one-to-one counselling cost £2,600 per QALY gained and group support cost £4,800 per QALY gained.
The frequency of smoking cessation among smokers varies across countries. Smoking cessation increased in Spain between 1965 and 2000, in Scotland between 1998 and 2007, and in Italy after 2000. In contrast, in the U.S. the cessation rate was "stable (or varied little)" between 1998 and 2008, and in China smoking cessation rates declined between 1998 and 2003.
Nevertheless, in a growing number of countries there are now more ex-smokers than smokers. In the United States, 61.7% of adult smokers (55.0 million adults) who had ever smoked had quit by 2018, an increase from 51.7% in 2009. As of 2020, the CDC reports that the number of adults who smoke in the U.S. has fallen to 30.8 million.
^ abcEdwards SA, Bondy SJ, Callaghan RC, Mann RE (March 2014). "Prevalence of unassisted quit attempts in population-based studies: a systematic review of the literature". Addictive Behaviors. 39 (3): 512–519. doi:10.1016/j.addbeh.2013.10.036. PMID24333037.
^Frazer K, McHugh J, Callinan JE, Kelleher C (May 2016). "Impact of institutional smoking bans on reducing harms and secondhand smoke exposure". The Cochrane Database of Systematic Reviews (5): CD011856. doi:10.1002/14651858.CD011856.pub2. PMID27230795.
^Baskerville NB, Azagba S, Norman C, McKeown K, Brown KS (March 2016). "Effect of a Digital Social Media Campaign on Young Adult Smoking Cessation". Nicotine & Tobacco Research. 18 (3): 351–360. doi:10.1093/ntr/ntv119. PMID26045252.
^Hettema JE, Hendricks PS (December 2010). "Motivational interviewing for smoking cessation: a meta-analytic review". Journal of Consulting and Clinical Psychology. 78 (6): 868–884. doi:10.1037/a0021498. PMID21114344.
^Prochaska JO, Velicer WF, DiClemente CC, Fava J (August 1988). "Measuring processes of change: applications to the cessation of smoking". Journal of Consulting and Clinical Psychology. 56 (4): 520–528. doi:10.1037/0022-006X.56.4.520. PMID3198809.
^Gonzales D, Redtomahawk D, Pizacani B, Bjornson WG, Spradley J, Allen E, Lees P (February 2007). "Support for spirituality in smoking cessation: results of pilot survey". Nicotine & Tobacco Research. 9 (2): 299–303. doi:10.1080/14622200601078582. PMID17365761.
^Leeks KD, Hopkins DP, Soler RE, Aten A, Chattopadhyay SK (February 2010). "Worksite-based incentives and competitions to reduce tobacco use. A systematic review". American Journal of Preventive Medicine. 38 (2 Suppl): S263–S274. doi:10.1016/j.amepre.2009.10.034. PMID20117611.
^Papadakis S, McDonald P, Mullen KA, Reid R, Skulsky K, Pipe A (2010). "Strategies to increase the delivery of smoking cessation treatments in primary care settings: a systematic review and meta-analysis". Preventive Medicine. 51 (3–4): 199–213. doi:10.1016/j.ypmed.2010.06.007. PMID20600264.
^He D, Berg JE, Høstmark AT (March 1997). "Effects of acupuncture on smoking cessation or reduction for motivated smokers". Preventive Medicine. 26 (2): 208–214. doi:10.1006/pmed.1996.0125. PMID9085389.
^Baggett TP, Tobey ML, Rigotti NA (July 2013). "Tobacco use among homeless people--addressing the neglected addiction". The New England Journal of Medicine. 369 (3): 201–204. doi:10.1056/NEJMp1301935. PMID23863048.
^Condiotte MM, Lichtenstein E (October 1981). "Self-efficacy and relapse in smoking cessation programs". Journal of Consulting and Clinical Psychology. 49 (5): 648–658. doi:10.1037/0022-006X.49.5.648. PMID7287974.
^Agboola SA, Coleman T, McNeill A, Leonardi-Bee J (July 2015). "Abstinence and relapse among smokers who use varenicline in a quit attempt-a pooled analysis of randomized controlled trials". Addiction. 110 (7): 1182–1193. doi:10.1111/add.12941. PMID25846123.
^Zaso, Michelle J.; Hendershot, Christian S. (September 2022). "Effects of varenicline and bupropion on laboratory smoking outcomes: Meta-analysis of randomized, placebo-controlled human laboratory studies". Addiction Biology. 27 (5): e13218. doi:10.1111/adb.13218. ISSN1369-1600. PMC 9413474. PMID36001439.
^Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
^ abSmoking cessation: A report of the surgeon general—executive summary. US Public Health Service; US Department of Health and Human Services, Rockville, MD 2020.
^Mills E, Eyawo O, Lockhart I, Kelly S, Wu P, Ebbert JO (February 2011). "Smoking cessation reduces postoperative complications: a systematic review and meta-analysis". The American Journal of Medicine. 124 (2): 144–154.e8. doi:10.1016/j.amjmed.2010.09.013. PMID21295194.
^Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T (December 1997). "Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research". JAMA. 278 (21): 1759–1766. doi:10.1001/jama.278.21.1759. PMID9388153.
^Bauld L, Boyd KA, Briggs AH, Chesterman J, Ferguson J, Judge K, Hiscock R (February 2011). "One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services". Nicotine & Tobacco Research. 13 (2): 135–145. doi:10.1093/ntr/ntq222. PMID21196451.
^Schiaffino A, Fernández E, Kunst A, Borrell C, García M, Borràs JM, Mackenbach JP (2007). "Time trends and educational differences in the incidence of quitting smoking in Spain (1965-2000)". Preventive Medicine. 45 (2–3): 226–232. doi:10.1016/j.ypmed.2007.05.009. PMID17604832.